Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VALEANT PHARMACEUTICALS INTL INC T.VRX

"Valeant Pharmaceuticals is a global specialty pharmaceutical firm with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The firm also has a branded generics business that operates primarily in Latin America, Eastern Europe, and Asia."


TSX:VRX - Post by User

Post by Johnnysbackon Nov 02, 2016 7:58am
62 Views
Post# 25414256

Probably a done deal

Probably a done deal

Deal is likely going to happen.......

Takeda tried earlier this year to buy Salix as part of a joint bid with private equity firm TPG but the approach, which came a few weeks before Mr. Papa took over as chief executive, was rejected by the board. They wanted to give Papa time to map out a course for the company.

Takeda said in September that it was scouting for multibillion-dollar acquisitions in the United States and other overseas markets as it seeks to boost its core therapy areas, including gastrointestinal medicine.

<< Previous
Bullboard Posts
Next >>